A dual-receptor T cell therapy platform that distinguishes tumor cells from normal cells by integrating activator and blocker signals based on tumor-specific gene losses.

An autologous Tmod™ cell therapy targeting carcinoembryonic antigen (CEA) with a blocker for HLA-A*02 to selectively kill tumor cells in colorectal, pancreatic, and non-small cell lung cancers.